Transforming growth factor-beta1 suppresses hepatocellular carcinoma proliferation via activation of Hippo signaling

Area of Science:

• Oncology
• Molecular Biology
• Cell Signaling

Background:

• Hepatocellular carcinoma (HCC) remains a significant global health challenge.
• Understanding the molecular mechanisms underlying HCC progression is crucial for developing effective therapies.
• The Hippo signaling pathway and transforming growth factor-β 1 (TGF-β1) are implicated in various cancers, including HCC.

Purpose of the Study:

• To investigate the role of the Hippo signaling pathway in TGF-β1-treated HCC cells.
• To elucidate the relationship between TGF-β1 and core Hippo pathway proteins in HCC.
• To explore potential therapeutic strategies for HCC based on these interactions.

Main Methods:

• Treatment of HCC cells with TGF-β1.
• Analysis of core Hippo signaling pathway protein expression.
• Assessment of Large tumor suppressor 1 (LATS1) expression levels.
• Evaluation of YAP1 (Yes-associated protein 1) localization (nuclear vs. cytoplasmic).

Main Results:

• TGF-β1 treatment induced overexpression of LATS1 in HCC cells.
• TGF-β1 treatment caused the translocation of YAP1 from the nucleus to the cytoplasm.
• The Hippo signaling pathway was confirmed to be involved in TGF-β1-induced inhibition of HCC cell growth.
• Overexpression of LATS1 and nucleocytoplasmic translocation of YAP1 demonstrated an anti-oncogenetic role.

Conclusions:

• The Hippo signaling pathway plays a critical role in TGF-β1's anti-proliferative effects on HCC.
• LATS1 overexpression and YAP1 cytoplasmic translocation are key events in this process.
• These findings offer novel insights into potential therapeutic targets for liver cancer treatment.